I normally don't repost posts from other boards, b
Post# of 148294
(Total Views: 5064)
Posted On: 07/07/2020 7:17:02 AM
I normally don't repost posts from other boards, but in this case, I'll make an exception. This was posted by a first-time poster.
elonmarx Tuesday, 07/07/20 12:46:07 AM
Re: None 0
Post # 91465 of 91499
I'm an MD and I generally stay away from Biotechs due to intense speculation and so many variables that exist between product inception and approval that are out of ones control.
With CYDY I think for the first time in my career I have truly seen the stars align.
Let me begin by saying I am NOT a savvy investor with formal investment training, access to the best financial firms or legions of analysts from B-school. Therefore, my decision to invest rests HEAVILY on the science itself. So far, it has served me well.
Leronlimab truly is a gem of a drug, which without exaggeration could end a pandemic, revive economies, and alter the course of modern medicine. However, I think most of us are unable to visualize the extent of its possible impact. Imagine asking Alexander Fleming how his mouldy petri dish would change the world. This drug very well may be to T cell mediated / autoimmune processes what penicillin is to bacterial diseases.
The usage of leronlimab to treat the auto inflammatory state triggered by covid was a stroke of genius. I think Dr. Seethamraju was brilliant in using this therapy, and I think Dr. Bruce Patterson's team was brilliant in recognizing the marked elevation of RANTES (the CCR5 ligand) in these patients.
What absolutely sold me on the mechanism of action was the fact that out of curiosity I decided to question the other findings of COVID-19. What about those kids with the Kawasaki-type syndromes? what about those mysterious petechial rashes?
I did my own research on PubMed and guess what? There is plenty of evidence from the early 2000s and before, that RANTES is significantly elevated in Kawasaki's disease. Guess what else i'ts elevated in? Henoch-Schonlein purpura.
The fact that the elevated RANTES was identified independently of this association with a kawasaki-type syndrome, really brings it home for me.
Lastly, if this is true, then Kawasaki syndrome and HSP are both likely triggered by a viral insult, which then results in upregulation in RANTES production and the recruitment of T cells to the area and resultant overproduction of inflammatory molecules.
Many autoimmune conditions are likely a combination of genetic predisposition coupled with a viral or environmental trigger. The reason why most people aren't grasping the magnitude of this discovery is because they don't realize the sheer number of auto-immune processes which up until now have had no clear trigger, and no real clear mechanism by which to treat safely and effectively.
I am absolutely a believer in the science, and only the science. Do your own research, but drugs like this don't come often. I hope its the real deal and some unforeseen political force doesn't keep it from realizing its full potential.
Really appreciate everyones thoughtful commentary on this board.
elonmarx Tuesday, 07/07/20 12:46:07 AM
Re: None 0
Post # 91465 of 91499
I'm an MD and I generally stay away from Biotechs due to intense speculation and so many variables that exist between product inception and approval that are out of ones control.
With CYDY I think for the first time in my career I have truly seen the stars align.
Let me begin by saying I am NOT a savvy investor with formal investment training, access to the best financial firms or legions of analysts from B-school. Therefore, my decision to invest rests HEAVILY on the science itself. So far, it has served me well.
Leronlimab truly is a gem of a drug, which without exaggeration could end a pandemic, revive economies, and alter the course of modern medicine. However, I think most of us are unable to visualize the extent of its possible impact. Imagine asking Alexander Fleming how his mouldy petri dish would change the world. This drug very well may be to T cell mediated / autoimmune processes what penicillin is to bacterial diseases.
The usage of leronlimab to treat the auto inflammatory state triggered by covid was a stroke of genius. I think Dr. Seethamraju was brilliant in using this therapy, and I think Dr. Bruce Patterson's team was brilliant in recognizing the marked elevation of RANTES (the CCR5 ligand) in these patients.
What absolutely sold me on the mechanism of action was the fact that out of curiosity I decided to question the other findings of COVID-19. What about those kids with the Kawasaki-type syndromes? what about those mysterious petechial rashes?
I did my own research on PubMed and guess what? There is plenty of evidence from the early 2000s and before, that RANTES is significantly elevated in Kawasaki's disease. Guess what else i'ts elevated in? Henoch-Schonlein purpura.
The fact that the elevated RANTES was identified independently of this association with a kawasaki-type syndrome, really brings it home for me.
Lastly, if this is true, then Kawasaki syndrome and HSP are both likely triggered by a viral insult, which then results in upregulation in RANTES production and the recruitment of T cells to the area and resultant overproduction of inflammatory molecules.
Many autoimmune conditions are likely a combination of genetic predisposition coupled with a viral or environmental trigger. The reason why most people aren't grasping the magnitude of this discovery is because they don't realize the sheer number of auto-immune processes which up until now have had no clear trigger, and no real clear mechanism by which to treat safely and effectively.
I am absolutely a believer in the science, and only the science. Do your own research, but drugs like this don't come often. I hope its the real deal and some unforeseen political force doesn't keep it from realizing its full potential.
Really appreciate everyones thoughtful commentary on this board.
(29)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼